ThromboGenics: Clinical Trials

3 trials sponsored by ThromboGenics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3

Follow ThromboGenics: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Ocriplasmin, Sham injection - Vitreomacular Adhesion Including Macular Hole
Phase 3CompletedThromboGenics2202011-10-012016-03-14
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Ocriplasmin 125µg, Placebo - Vitreomacular Adhesion
Phase 3CompletedThromboGenics3262008-12-012014-12-17
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.
125 µg Ocriplasmin, Placebo - Vitreomacular Adhesion
Phase 3CompletedThromboGenics3262008-12-012014-12-17

Interventions

microplasmin (3)  ·  salicylhydroxamic acid (1)

Countries

United States (3)  ·  Belgium (1)  ·  Czechia (1)  ·  Germany (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 22879421, PMID 22894573, PMID 23033391, PMID 26068086, PMID 30350717, PMID 34250257